You have 9 free searches left this month | to do more
Showing 1 - 25 of
6,632 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
T
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
Active, not recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
2021-12-30
Dec 30, 2021
F
HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma
Recruiting
  • Lymphoma
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
2021-04-16
Apr 16, 2021
J
GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma - 2022
Completed
  • Lymphoma, Non-Hodgkin
  • Obinutuzumab and Pixantrone
  • Mainz, RLP, Germany
    Department of Hematology, Oncology and Pneumology; University Me
2022-03-30
Mar 30, 2022
U
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
Recruiting
  • Relapsed Non Hodgkin Lymphoma
  • +2 more
  • autologous CD19-directed chimeric antigen receptor (CAR) T-cells
  • Calgary, Alberta, Canada
  • +5 more
2021-07-16
Jul 16, 2021
U
TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Active, not recruiting
  • Non Hodgkin Lymphoma
  • Cologne, Germany
  • +1 more
2022-03-02
Mar 2, 2022
T
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Recruiting
  • CLL
  • +9 more
  • TG-1801
  • Ublituximab
  • Fayetteville, Arkansas
  • +4 more
2022-03-22
Mar 22, 2022
L
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Not yet recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +2 more
  • Miami, Florida
    University of Miami
2022-04-05
Apr 5, 2022
M
Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy
Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
2021-04-30
Apr 30, 2021
I
GVM±R in Patients With Relapsed or Refractory Aggressive NHL
Not yet recruiting
  • Non Hodgkin Lymphoma
  • Liposomal Mitoxantrone Hydrochloride dose level 1
  • +6 more
  • (no location specified)
2022-03-17
Mar 17, 2022
S
Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
Recruiting
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • +4 more
  • Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
  • R-CHOP; R-DA-EPOCH; R-HD MTX
  • Jinan, Shandong, China
    Department of Hematology, Shandong Provincial Hospital
2021-12-07
Dec 7, 2021
W
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma
  • New York, New York
    Weill Cornell Medical College
2021-09-20
Sep 20, 2021
N
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-31
Mar 31, 2022
S
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
Recruiting
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
  • +4 more
  • Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
  • Jinan, Shandong, China
    Shandong Provincial Hospital
2021-11-18
Nov 18, 2021
S
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma - 2010
Completed
  • Non-Hodgkin's Lymphoma
  • +3 more
  • Nagoya-city, Aichi, Japan
  • +3 more
2021-07-01
Jul 1, 2021
H
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Recruiting
  • Non-Hodgkin Lymphoma
  • Busan, Korea, Republic of
    Pusan National University Hospital
2022-03-24
Mar 24, 2022
N
Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma
Not yet recruiting
  • Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation
  • +18 more
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Chicago, Illinois
  • +2 more
2022-01-18
Jan 18, 2022
N
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Recruiting
  • Lymphoma, Non-Hodgkin
  • +9 more
  • NKX019
  • Denver, Colorado
  • +6 more
2022-01-19
Jan 19, 2022
M
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-22
Nov 22, 2021
S
Zevalin-beam for Aggressive Lymphoma - 2015
Completed
Has Results
  • Non-Hodgkin's Lymphoma
  • ibritumomab tiuxetan
  • BEAM chemotherapy and autologous stem-cell transplantation
  • Scottsdale, Arizona
  • +8 more
2020-08-13
Aug 13, 2020
I
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Recruiting
  • Diffuse Large B Cell Lymphoma
  • +2 more
  • Changsha, Hunan, China
  • +5 more
2022-01-24
Jan 24, 2022
C
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Recruiting
  • Lymphoma, B-Cell
  • Vancouver, British Columbia, Canada
  • +2 more
2022-01-24
Jan 24, 2022
G
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL - 2017
Withdrawn
  • Non Hodgkin's Lymphoma
  • +3 more
  • Veltuzumab and 90Y-Epratuzumab Tetraxetan
  • +2 more
  • Newark, Delaware
  • +6 more
2021-08-12
Aug 12, 2021
U
CD34+ Selected ASCT for Aggressive Lymphomas
Active, not recruiting
  • Malignant Non-Hodgkin Lymphomas
  • CD34+ cell selection
  • Berne, Switzerland
    Department for Medical Oncology; University Hospital/Inselspital
2021-07-29
Jul 29, 2021
N
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Recruiting
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
U
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma - 2012
Completed
  • Lymphoma
  • pegfilgrastim
  • +5 more
  • (no location specified)
2021-07-02
Jul 2, 2021